Investigating new treatment combinations for rectal cancer using radiation and immunotherapy
Early response to radiotherapy and immunotherapy in rectal cancer: an integrated molecular, cellular, and spatial approach
This study is looking for ways to help people with locally advanced rectal cancer by testing a new treatment that combines radiation, chemotherapy, and an innovative immune-boosting drug called αCD40, with the hope of improving outcomes and possibly avoiding surgery.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ut Southwestern Medical Center NIH-funded |
| Lab location | 1 site (Dallas, United States) |
| Project ID | NIH-10894130 on NIH RePORTER |
What this research studies
This research focuses on improving treatment outcomes for patients with locally advanced rectal cancer by exploring the effectiveness of combining radiation therapy and chemotherapy with a novel immunotherapy agent called αCD40. The study aims to personalize treatment approaches to enhance the body's immune response against cancer cells, potentially allowing for non-operative management of the disease. Patients will be involved in a phase II clinical trial that evaluates the safety and efficacy of these combined therapies. By analyzing tumor responses and immune system interactions, the research seeks to identify the best treatment strategies for this challenging cancer type.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with locally advanced rectal cancer who are eligible for neoadjuvant therapy.
Not a fit: Patients with early-stage rectal cancer or those who have already undergone extensive treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for rectal cancer, potentially improving survival rates and reducing the need for surgery.
How similar studies have performed: Previous research has shown promise in using immunotherapy in combination with other treatments for various cancers, but this specific approach in rectal cancer is relatively novel.
Where this research is happening
Dallas, United States
- Ut Southwestern Medical Center — Dallas, United States (Active)
Researchers
- Principal investigator: Aguilera, Todd a — Ut Southwestern Medical Center
- Study coordinator: Aguilera, Todd a
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.